{"id":540036,"date":"2021-04-22T17:50:02","date_gmt":"2021-04-22T17:50:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=540036"},"modified":"2021-04-22T17:50:02","modified_gmt":"2021-04-22T17:50:02","slug":"follicular-lymphoma-market-epidemiology-and-market-forecast-analysis-report","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-epidemiology-and-market-forecast-analysis-report_540036.html","title":{"rendered":"Follicular Lymphoma Market, Epidemiology, and Market Forecast Analysis Report"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Follicular Lymphoma Market, Epidemiology, and Market Forecast Analysis Report\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Follicular Lymphoma Market, Epidemiology, and Market Forecast Analysis Report\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.\n<\/div>\n<p style=\"text-align: justify;\"><strong>What is Follicular Lymphoma?<\/strong><\/p>\n<p style=\"text-align: justify;\">Follicular lymphoma, a B-cell lymphoma, is the second most common type of low-grade non-Hodgkin lymphoma (NHL). The transformation of a B-cell characterizes it into a malignant cell. Abnormal, uncontrolled growth and proliferation of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs. &nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;What are Follicular Lymphoma causes?<\/strong><\/p>\n<p style=\"text-align: justify;\">Follicular Lymphoma causes are not known. Unlike some cancers, they are not passed down in families. In some cases, radiation or cancer-causing chemicals, or certain infections, may be a cause. But other times there is no known cause.<\/p>\n<p style=\"text-align: justify;\"><strong>What are the symptoms of Follicular Lymphoma?<\/strong><\/p>\n<p style=\"text-align: justify;\">Follicular Lymphoma symptoms include painless swelling of the lymph nodes in your neck, groin, stomach, or armpits, shortness of breath, fatigue, night sweats, and weight loss.<\/p>\n<p style=\"text-align: justify;\"><strong>How Follicular Lymphoma affected population?<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Follicular Lymphoma Epidemiology<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to DelveInsight&rsquo;s analysis, the total prevalent population of Follicular Lymphoma in seven major markets was&nbsp;<strong>33,363<\/strong>&nbsp;in 2017. These cases are expected to increase with a significant CAGR during the study period (2017&ndash;2030).<\/li>\n<li>Among all the seven major markets, the United States accounts for the highest number of Follicular Lymphoma cases<strong>.<\/strong><\/li>\n<li>In the US, the Follicular Lymphoma cases were&nbsp;<strong>14,329&nbsp;<\/strong>in 2017. Moreover, the grade-specific cases of Follicular Lymphoma were highest among grade I and were reported to be 5,198 cases.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">To know more, request sample pages @<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" ><strong>Follicular Lymphoma Market Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Follicular Lymphoma Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/df43e6bf6fa1d0c764ae8314faaf4360.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">According to DelveInsight, the&nbsp;<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" ><strong>Follicular Lymphoma market size<\/strong><\/a>&nbsp;is expected to increase at a significant CAGR during the study period (2017&ndash;2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with&nbsp;<strong>USD 799 million<\/strong>&nbsp;in 2017, while Spain had the smallest market size of Follicular Lymphoma with&nbsp;<strong>USD 56 million<\/strong>&nbsp;in 2017<strong>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>What are the present Follicular Lymphoma market drivers?<\/strong><\/p>\n<p style=\"text-align: justify;\">Changing standards of care, increasing opportunities and family history aims at driving the market growth.<\/p>\n<p style=\"text-align: justify;\"><strong>What are the Follicular Lymphoma market barriers?<\/strong><\/p>\n<p style=\"text-align: justify;\">Clinical heterogeneity, economic burden of the disease and adverse effects of the therapies are some limitations to the&nbsp;<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" ><strong>Follicular Lymphoma Market Growth<\/strong><\/a>.<\/p>\n<p style=\"text-align: justify;\"><strong>Which are the leading companies in Follicular Lymphoma market?<\/strong><\/p>\n<p style=\"text-align: justify;\">Key Players such as Epizyme, Kite Pharma, Novartis, Roche, Regeneron, TG therapeutics, MEI Pharma, Incyte Corporation, Bayer Health, Verastem Oncology, Gilead Sciences, Xynomics Pharmaceuticals, Bristol Myeres, Takeda Oncology, and others are the leading companies in Follicular Lymphoma market.<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">3. SWOT Analysis for Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">4. Follicular Lymphoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">7. Country Wise-Epidemiology of Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">8. Treatment<\/p>\n<p style=\"text-align: justify;\">9. Guidelines<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Organizations contributing toward Follicular Lymphoma<\/p>\n<p style=\"text-align: justify;\">12. Patient Journey<\/p>\n<p style=\"text-align: justify;\">13. Case Reports<\/p>\n<p style=\"text-align: justify;\">14. Marketed Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.1. Tazverik: Epizyme<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.2. Aliqopa: Bayer Healthcare Pharmaceuticals<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.3. Copiktra: Verastem Oncology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.4. Zydelig: Gilead Sciences<\/p>\n<p style=\"text-align: justify;\">15. Combinational Therapies: Marketed<\/p>\n<p style=\"text-align: justify;\">16. Emerging Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1. Abexinostat: Xynomic Pharmaceuticals, Inc.<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2. Umbralisib: TG Therapeutics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.3. ME-401: MEI Pharma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.4. Odronextamab: Regeneron Pharmaceuticals<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.5. Parsaclisib: Incyte Corporation<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.6. Kymriah: Novartis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.7. Yescarta: Kite Pharma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.8. Nivolumab: Bristol-Myers Squibb<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.9. Ixazomib &#8211; Takeda Oncology<\/p>\n<p style=\"text-align: justify;\">17. Emerging Combinational Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.1. Ibrutinib + Rituximab<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.2. Umbralisib + Ublituximab + Bendamustine<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17.3. Zanubrutinib + Obinutuzumab<\/p>\n<p style=\"text-align: justify;\">18. Other Promising Therapies<\/p>\n<p style=\"text-align: justify;\">19. Follicular Lymphoma: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">20. Market Outlook<\/p>\n<p style=\"text-align: justify;\">21. Market Drivers<\/p>\n<p style=\"text-align: justify;\">22. Market Barriers<\/p>\n<p style=\"text-align: justify;\">23. Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">24. Appendix<\/p>\n<p style=\"text-align: justify;\">25. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">26. Disclaimer<\/p>\n<p style=\"text-align: justify;\">27. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">Request sample pages for more information on&nbsp;<strong><a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" >Follicular Lymphoma Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=follicular-lymphoma-market-epidemiology-and-market-forecast-analysis-report\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=follicular-lymphoma-market-epidemiology-and-market-forecast-analysis-report\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-epidemiology-and-market-forecast-analysis-report_540036.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-540036","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=540036"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540036\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=540036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=540036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=540036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}